leadf
logo-loader
viewBetterLife Pharma Inc

BetterLife Pharma encouraged by results of UK biotech's trial of interferon inhalation treatment for coronavirus

The UK trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given a placebo

Synairgen PLC -
The treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus, noted BetterLife

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) has hailed the positive results from a clinical trial by a UK biotech, which suggested that an interferon inhalation treatment for coronavirus (COVID-19) reduces the need for intensive care.

Data from the Synairgen PLC (LON:SNG) trial showed that people who received SNG001, an inhaled formulation of interferon beta, had a 79% lower risk of developing severe coronavirus disease compared to those given the placebo.

READ: Synairgen rockets as trial results could signal "major breakthrough" in treatment of severely ill COVID-19 patients

They were also more than twice as likely to recover from the illness than those receiving the substance with no therapeutic value.

The treatment was delivered through a nebulizer and inhaled directly into the lungs of patients with coronavirus, noted BetterLife in a statement on Tuesday.

BetterLife is an advocate of using interferons to treat coronavirus, particularly delivered by an inhalation device.

It is aiming to carry out a clinical trial this summer to test to treat patients afflicted with the virus and hopes the nebulizer, along with its patent-pending interferon alpha2b drug, called AP-003, will help patients.

The treatment in the Synairgen study used interferon beta, as opposed to the alpha 2b (IFN-a2b) treatment developed by the company.

"We are encouraged by the positive results from this trial as it further confirms the proof of concept of anti-COVID treatment via IFN inhalation," Ahmad Doroudian, the chief executive officer of BetterLife said in the statement. "We look forward to our proposed 150 patient clinical trials using AP-003 (inhaled IFN alpha 2b) in COVID-19 patients."

He added: "BetterLife’s team believes that the isoform-free IFN alpha2b will provide a potentially superior treatment regimen for Covid-19 patients, as IFN-a2b has already been used to successfully treat other viral infections such as HCV and HBV."

Shares in Toronto gained over 4.6% to C$2.46. 

---Updates for share price---

Contact the author at [email protected]

Quick facts: BetterLife Pharma Inc

Price: 0.52 USD

OTCQB:BETRF
Market: OTCQB
Market Cap: $9.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

BetterLife Pharma reveals clinical trial updates on its treatment for...

BetterLife Pharma Inc (OTCQB:BETRF) (CSE:BETR) CEO Ahmad Doroudian updates Proactive on the group's clinical trials progress, revealing it has engaged the clinical research organization Pharmaceutical Solutions Ltd to manage its study of AP-003 as a treatment for mild-to-moderate...

on 10/16/2020

2 min read